SCM
ZBIO

Silverarc Capital Management’s Zenas BioPharma ZBIO Stock Holding History

Silverarc Capital Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Sell
509,789
-626,146
-55% -$12.4M 1.34% 24
2026
Q1 		$22.2M Buy
+1,135,935
New +$25.5M 2.27% 16

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Silverarc Capital Management's ZBIO Position: Q2 2026 in Review

Silverarc Capital Management reduced its Zenas BioPharma (ZBIO) stake by 55% in Q2 2026, selling an estimated $12.4M and leaving 509,789 shares worth $12.9M. The position accounts for 1.34% of the portfolio, ranked #24.

Silverarc Capital Management first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $22.2M in Q1 2026. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Silverarc Capital Management held 509,789 shares of Zenas BioPharma worth $12.9M as of Q2 2026.
  • Silverarc Capital Management sold 626,146 Zenas BioPharma shares in Q2 2026, an estimated $12.4M.
  • Zenas BioPharma made up 1.34% of Silverarc Capital Management's portfolio in Q2 2026, its #24 holding.
  • Silverarc Capital Management first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • Silverarc Capital Management's Zenas BioPharma position peaked at $22.2M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.